Pulsatile high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer

Neuro-Oncology

Volumn 13, Issue 12, 2011, Pages 1364-1369

  Grommes, Christian ^a,d   Oxnard, Geoffrey R ^b,c   Kris, Mark G ^c   Miller, Vincent A ^c,e   Pao, William ^c   Holodny, Andrei I ^d,e   Clarke, Jennifer L ^a   Lassman, Andrew B ^e  

^a Department of Neurology ^*  (United States)

^b Neuroradiology Service   (United States)

^c Thoracic Oncology Service   (United States)

^d Brain Tumor Center   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

CNS metastases; EGFR; Erlotinib; Lung cancer; Pulsatile dosing.

Indexed keywords

ERLOTINIB; VASCULOTROPIN RECEPTOR;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN METASTASIS; CANCER PATIENT; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; FATIGUE; FEMALE; HUMAN; LUNG; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALE; MENINGEAL METASTASIS; MUTANT; MUTATION; NAUSEA; OVERALL SURVIVAL; PROSPECTIVE STUDY; PULSATILE DRUG RELEASE; RASH; RETROSPECTIVE STUDY;

EID: 84856304068     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nor121     Document Type: Article

References (22)

1. Pao W, Miller VA. Epidermal growth factor receptor mutations, smallmolecule kinase inhibitors, and non-small-cell lung cancer: Current knowledge and future directions. J Clin Oncol. 2005;23:2556-2568.
2. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129-2139. (Pubitemid 38637993)
3. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science. 2004;304:1497-1500. (Pubitemid 38720929)
4. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004;101:13306-13311. (Pubitemid 39209661)
5. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7:169-181.
6. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005;2:e73.
7. Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA. 2007;104: 20932-20937.
8. Heon S, Yeap BY, Britt GJ, et al. Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2010;16:5873-5882.
9. Omuro AM, Kris MG, Miller VA, et al. High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer. 2005;103:2344-2348. (Pubitemid 40686581)
10. Eichler AF, Kahle KT, Wang DL, et al. EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Neuro Oncol. 2010;12:1193-1199.
11. Jackman DM, Holmes AJ, Lindeman N, et al. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with highdose gefitinib. J Clin Oncol. 2006;24:4517-4520. (Pubitemid 46630993)
12. Clarke JL, PaoW, Wu N, Miller VA, Lassman AB. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol. 2010;99:283-286.
13. Milton DT, Azzoli CG, Heelan RT, et al. A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer. Cancer. 2006;107:1034-1041. (Pubitemid 44291152)
14. Shah NP, Kasap C,Weier C, et al. Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell. 2008;14:485-493.
15. Chien AJ, Illi JA, Ko AH, et al. A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies. Clin Cancer Res. 2009;15: 5569-5575.
16. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247.
17. Pan Q, Pao W, Ladanyi M. Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn. 2005;7:396-403. (Pubitemid 41149655)
18. Macdonald DR, Cascino TL, Schold SC, Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277-1280. (Pubitemid 20195640)
19. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group. J Clin Oncol. 2010;28:1963-1972.
20. Watling CJ, Lee DH, Macdonald DR, Cairncross JG. Corticosteroidinduced magnetic resonance imaging changes in patients with recurrent malignant glioma. J Clin Oncol. 1994;12:1886-1889. (Pubitemid 24349391)
21. Mehta MP, Rodrigus P, Terhaard CH, et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and wholebrain radiation therapy in brain metastases. J Clin Oncol. 2003;21: 2529-2536. (Pubitemid 46606335)
22. Balak MN, Gong Y, Riely GJ, et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res. 2006;12:6494-6501. (Pubitemid 44799723)